Key facts
- This page summarizes Scott Dunseth Myers's Form 4 filing for Cartesian Therapeutics, Inc. (RNAC).
- 5 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 15 Nov 2023, 17:16.
Scott Dunseth Myers - 13 Nov 2023 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)
- Reporting relationship
- Director
- Issuer ticker
- RNAC
- Reported as of
- 13 Nov 2023
- Net transaction value
- -$81,375
- SEC form
- 4
- Accepted by SEC
- 15 Nov 2023, 17:16:10 UTC
- Prior SEC filing
- 02 Oct 2023
- Next SEC filing
- 28 Nov 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Matthew Bartholomae, Attorney-in-Fact for Scott Dunseth Myers
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Scott Dunseth Myers filed Form 4 for Cartesian Therapeutics, Inc. (RNAC) on 15 Nov 2023.
Change
- Previous filing in this sequence was filed on 02 Oct 2023.
- Current net transaction value: -$81,375.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SELB
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -20,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 13 Nov 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,000
- Exercise price
- $2.10
- Footnotes
- F1
SELB
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -20,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 13 Nov 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,000
- Exercise price
- $3.00
- Footnotes
- F2
SELB
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -40,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 13 Nov 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 40,000
- Exercise price
- $4.01
- Footnotes
- F3
SELB
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -40,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 13 Nov 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 40,000
- Exercise price
- $3.31
- Footnotes
- F4
SELB
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- $81,375
- Shares
- -87,500
- Change %
- -100%
- Price
- $0.9300
- Shares after
- 0
- Date
- 13 Nov 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 87,500
- Exercise price
- $1.13
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
This option, which provided for vesting in thirty-six (36) substantially equal monthly installments over three years following the date of grant on June 14, 2019, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc.
Footnote F2
This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger.
Footnote F3
This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger.
Footnote F4
This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger.
Footnote F5
This option, which provided for vesting in full on January 2, 2024, was canceled in the Merger in exchange for a cash payment of $81,375, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger.